Sign in Register

Drug class

Pulmonary Antihypertensive Agents, cGMP pathway

Pulmonary antihypertensive agents targeting the cyclic guanosine monophosphate (cGMP) pathway are cardiovascular medications that promote pulmonary vascular relaxation and reduce vascular remodeling. Read more about Pulmonary Antihypertensive Agents, cGMP pathway

84 drugs in this class 48 manufacturers

Related classes & indications

Calcium Channel BlockersCardiovascular & renal · 344 prescription drugs Angiotensin II Receptor Antagonists (ARBs)Cardiovascular & renal · 281 prescription drugs Pulmonary Arterial HypertensionTop indication · 135 prescription drugs

Showing 64–72 of 84 drugs

Sort

SILDENAFIL CITRATE

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · PULMONARY ARTERIAL HYPERTENSION

SKY PHARMACEUTI

SILDENAFIL CITRATE

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · PULMONARY ARTERIAL HYPERTENSION

NUCARE PHARMACE

SILDENAFIL CITRATE

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · PULMONARY ARTERIAL HYPERTENSION

BLUEPOINT LABOR

SILDENAFIL CITRATE

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · PULMONARY ARTERIAL HYPERTENSION

ZYDUS PHARMACEU

SILDENAFIL CITRATE

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · PULMONARY ARTERIAL HYPERTENSION

NOVADOZ PHARMAC

SILDENAFIL CITRATE

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · PULMONARY ARTERIAL HYPERTENSION

XLCARE PHARMACE

SILDENAFIL CITRATE

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · ERECTILE DYSFUNCTION

ADVAGEN PHARMA

SILDENAFIL CITRATE

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · ERECTILE DYSFUNCTION

QUALLENT PHARMA

TADALAFIL

AGENTS TO TREAT ERECTILE DYSFUNCTION, CGMP-TYPE · BENIGN PROSTATIC HYPERPLASIA WITH LOWER URINARY TRACT SYMPTOM ·+1

QUALLENT PHARMA

Filter & compare in the drug finder → Opens the drug finder with Pulmonary Antihypertensive Agents, cGMP pathway preselected. Add indication or manufacturer filters there.

About Pulmonary Antihypertensive Agents, cGMP pathway.

Pulmonary antihypertensive agents targeting the cyclic guanosine monophosphate (cGMP) pathway are cardiovascular medications that promote pulmonary vascular relaxation and reduce vascular remodeling.

They function by augmenting intracellular cGMP concentrations within pulmonary arterial smooth muscle, either by preventing its enzymatic degradation via phosphodiesterase type 5 inhibition or by directly stimulating soluble guanylate cyclase to synthesize cGMP.

By facilitating smooth muscle relaxation and lowering pulmonary vascular resistance, these agents are indicated primarily for the management of pulmonary arterial hypertension (WHO Group 1) and chronic thromboembolic pulmonary hypertension (WHO Group 4).

nih.gov
Pulmonary antihypertensive agents targeting the cyclic guanosine monophosphate (cGMP) pathway are cardiovascular medications that promote pulmonary vascular relaxation and reduce vascular remodeling
nih.gov
Pulmonary antihypertensive agents targeting the cyclic guanosine monophosphate (cGMP) pathway are cardiovascular medications that promote pulmonary vascular relaxation and reduce vascular remodeling They function by augmenting intracellular cGMP concentrations within pulmonary arterial smooth muscle, either by preventing its enzymatic degradation via phosphodiesterase type 5 inhibition or by directly stimulating soluble guanylate cyclase to synthesize cGMP By facilitating smooth muscle relaxatio...
fda.gov
They function by augmenting intracellular cGMP concentrations within pulmonary arterial smooth muscle, either by preventing its enzymatic degradation via phosphodiesterase type 5 inhibition or by directly stimulating soluble guanylate cyclase to synthesize cGMP
nv.gov
They function by augmenting intracellular cGMP concentrations within pulmonary arterial smooth muscle, either by preventing its enzymatic degradation via phosphodiesterase type 5 inhibition or by directly stimulating soluble guanylate cyclase to synthesize cGMP
fda.gov
By facilitating smooth muscle relaxation and lowering pulmonary vascular resistance, these agents are indicated primarily for the management of pulmonary arterial hypertension (WHO Group 1) and chronic thromboembolic pulmonary hypertension (WHO Group 4)
fda.gov
By facilitating smooth muscle relaxation and lowering pulmonary vascular resistance, these agents are indicated primarily for the management of pulmonary arterial hypertension (WHO Group 1) and chronic thromboembolic pulmonary hypertension (WHO Group 4)
frontiersin.org
By facilitating smooth muscle relaxation and lowering pulmonary vascular resistance, these agents are indicated primarily for the management of pulmonary arterial hypertension (WHO Group 1) and chronic thromboembolic pulmonary hypertension (WHO Group 4)